The team of Prof. Guo Qinglong and Li Zhiyu, who developed the national Class I original new drug CPU-118 tablets with independent intellectual property rights against advanced liver cancer, has successfully passed the approval of the Center for Drug Evaluation (CDE) of the State Drug Administration and received the notice of clinical trial after twelve years of hard work. This is another important achievement of China in the field of original new drug research.
CPU-118 is an effective active monomer of traditional Chinese medicine, which is prepared by chemical total synthesis method. The results of preclinical in vitro and in vivo experimental studies showed that CPU-118 has strong anti-tumor activity and can inhibit the growth of a variety of tumor cells, and its anti-hepatocellular carcinoma activity is the strongest. The significant inhibitory effect of CPU-118 on the growth of hepatocellular carcinoma was further verified by a PDX model constructed from human liver cancer samples. In addition, CPU-118 significantly improved the anti-hepatocellular carcinoma effect of low-dose sorafenib and reduced the side effects of sorafenib alone. It was also found that CPU-118 can selectively kill hepatocellular carcinoma cells without affecting the growth of normal hepatocytes, and has a miraculous protective effect on normal tissues such as nerves, lungs, heart and blood vessels, which is not available with current chemotherapeutic drugs. Preliminary mechanism study shows that CPU-118 can target AFP, inhibit the expression of AFP in hepatocellular carcinoma cells and its binding with oncoprotein PTEN, thus inducing apoptosis of hepatocellular carcinoma cells. No similar product is available at home and abroad, which provides a new idea and optional drug for the treatment of liver cancer.
The clinical trial was conducted with CPU-118 tablets, which were administered orally once daily for 21 days, with a very high safety profile and good patient experience.
There are only a total of 30 places in the CPU-118 clinical country. The clinical trial will be carried out in 7 key hospitals in Shanghai, Henan, Jiangxi, Shandong, Zhejiang and Jiangsu provinces. After the patients are enrolled in the group, the consultation, examination and treatment involved during the treatment will be carried out in the designated tertiary hospitals under the guidance of experts (see below for the details of hospitals and experts), and the treatment fees for patients involved in the treatment process will be totally free!
Recruiting conditions.
1、Age 18-80 years old, gender is not limited
2. Patients with diagnosed malignant advanced tumors.
3、Living on their own, not more than 60% of the time in bed during the day
There are thousands of medical research teams around the world developing new drugs every year, and the new drugs listed every year are numerous, especially for cancer, which is a key research direction for medical scientists around the world, but for various reasons, ordinary people rarely come into contact with this kind of information, so it takes many years for many new research results to be used by ordinary patients.
If you also agree, please move your fingers to the people in need, perhaps you and I an inadvertent action can save a life!
